These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
447 related articles for article (PubMed ID: 33972238)
1. Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance. Darlow CA; Docobo-Perez F; Farrington N; Johnson A; McEntee L; Unsworth J; Jimenez-Valverde A; Gastine S; Kolamunnage-Dona R; de Costa RMA; Ellis S; Franceschi F; Standing JF; Sharland M; Neely M; Piddock L; Das S; Hope W Antimicrob Agents Chemother; 2021 Jun; 65(7):e0029321. PubMed ID: 33972238 [TBL] [Abstract][Full Text] [Related]
2. Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance. Darlow CA; Farrington N; Johnson A; McEntee L; Unsworth J; Jimenez-Valverde A; Kolamunnage-Dona R; Da Costa RMA; Ellis S; Franceschi F; Sharland M; Neely M; Piddock LJV; Das S; Hope W J Antimicrob Chemother; 2022 Apr; 77(5):1334-1343. PubMed ID: 35170719 [TBL] [Abstract][Full Text] [Related]
3. Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings. Darlow CA; McEntee L; Johnson A; Farrington N; Unsworth J; Jimenez-Valverde A; Jagota B; Kolamunnage-Dona R; Da Costa RMA; Ellis S; Franceschi F; Sharland M; Neely M; Piddock L; Das S; Hope W J Antimicrob Chemother; 2022 Nov; 77(12):3349-3357. PubMed ID: 36177766 [TBL] [Abstract][Full Text] [Related]
4. Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology and drug evaluation prospective substudy (BARNARDS). Thomson KM; Dyer C; Liu F; Sands K; Portal E; Carvalho MJ; Barrell M; Boostrom I; Dunachie S; Farzana R; Ferreira A; Frayne F; Hassan B; Jones E; Jones L; Mathias J; Milton R; Rees J; Chan GJ; Bekele D; Mahlet A; Basu S; Nandy RK; Saha B; Iregbu K; Modibbo F; Uwaezuoke S; Zahra R; Shirazi H; Syed NU; Mazarati JB; Rucogoza A; Gaju L; Mehtar S; Bulabula ANH; Whitelaw A; van Hasselt JGC; Walsh TR; Lancet Infect Dis; 2021 Dec; 21(12):1677-1688. PubMed ID: 34384533 [TBL] [Abstract][Full Text] [Related]
5. The potential of fosfomycin for multi-drug resistant sepsis: an analysis of in vitro activity against invasive paediatric Gram-negative bacteria. Williams PCM; Waichungo J; Gordon NC; Sharland M; Murunga S; Kamau A; Berkley JA J Med Microbiol; 2019 May; 68(5):711-719. PubMed ID: 30994430 [TBL] [Abstract][Full Text] [Related]
6. Development and application of neonatal physiology-based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment. Darlow CA; Parrott N; Peck RW; Hope W CPT Pharmacometrics Syst Pharmacol; 2024 Mar; 13(3):464-475. PubMed ID: 38108548 [TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy. Sime FB; Johnson A; Whalley S; Santoyo-Castelazo A; Montgomery AB; Walters KA; Lipman J; Hope WW; Roberts JA Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795380 [TBL] [Abstract][Full Text] [Related]
8. Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria. Darlow CA; da Costa RMA; Ellis S; Franceschi F; Sharland M; Piddock L; Das S; Hope W Paediatr Drugs; 2021 Sep; 23(5):465-484. PubMed ID: 34435316 [TBL] [Abstract][Full Text] [Related]
9. Cefotaxime/sulbactam plus gentamicin as a potential carbapenem- and amikacin-sparing first-line combination for neonatal sepsis in high ESBL prevalence settings. Readman JB; Acman M; Hamawandi A; Chiu CH; Sharland M; Lindsay JA; Standing JF J Antimicrob Chemother; 2023 Aug; 78(8):1882-1890. PubMed ID: 37283195 [TBL] [Abstract][Full Text] [Related]
10. Amikacin-fosfomycin at a five-to-two ratio: characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibiotics. Montgomery AB; Rhomberg PR; Abuan T; Walters KA; Flamm RK Antimicrob Agents Chemother; 2014 Jul; 58(7):3708-13. PubMed ID: 24752276 [TBL] [Abstract][Full Text] [Related]
11. Literature review on the distribution characteristics and antimicrobial resistance of bacterial pathogens in neonatal sepsis. Wang J; Zhang H; Yan J; Zhang T J Matern Fetal Neonatal Med; 2022 Mar; 35(5):861-870. PubMed ID: 32102584 [TBL] [Abstract][Full Text] [Related]
13. Activity of fosfomycin and amikacin against fosfomycin-heteroresistant Portillo-Calderón I; Ortiz-Padilla M; de Gregorio-Iaria B; Merino-Bohorquez V; Blázquez J; Rodríguez-Baño J; Rodríguez-Martínez JM; Pascual A; Docobo-Pérez F Antimicrob Agents Chemother; 2023 May; 65(5):. PubMed ID: 33685903 [No Abstract] [Full Text] [Related]
14. The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria. Li G; Standing JF; Bielicki J; Hope W; van den Anker J; Heath PT; Sharland M Drugs; 2017 Jun; 77(9):941-950. PubMed ID: 28456943 [TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of Piperacillin-Tazobactam/Amikacin Combination versus Meropenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow Fiber Infection Model. Islam K; Sime FB; Wallis SC; Bauer MJ; Naicker S; Won H; Zowawi HM; Choudhury MA; Shirin T; Habib ZH; Harris PNA; Flora MS; Roberts JA Antimicrob Agents Chemother; 2022 Sep; 66(9):e0016222. PubMed ID: 35924928 [TBL] [Abstract][Full Text] [Related]